Molecular basis for the development of novel taxanes in the treatment of metastatic breast cancer

European Journal of Cancer, Supplement

Volumn 6, Issue 10, 2008, Pages 3-11

  Aapro, Matti S ^a   Von Minckwitz, Gunter ^b  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Breast cancer; Docetaxel; Nab paclitaxel; Paclitaxel; Polyethylated castor oil; Polysorbate 80

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; ALBUMIN; ALPHA TOCOPHEROL; ANTHRACYCLINE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CREL PACLITAXEL; CREMOPHOR; CYTOTOXIC AGENT; DJ 927; DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; NAB PACLITAXEL; NAVELBINE; OC 144 093; PACLITAXEL; PACLITAXEL POLIGLUMEX; POLYSORBATE 80; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TESETAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BLURRED VISION; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DEMYELINATION; DERMATITIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRY EYE; DRY SKIN; DYSPNEA; EMULSION; FATIGUE; FLUID RETENTION; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; LIVER TOXICITY; MALAISE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA; VESICULAR DEGENERATION; VISUAL ACUITY; VOMITING;

EID: 50349088394     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(08)71921-9     Document Type: Article

References (56)

1. Rugo H.S. The importance of distant metastases in hormone-sensitive breast cancer. Breast 17 S1 (2008) S3-S8
2. World Health Organization. Cancer. Geneva, Switzerland: World Health Organization; [updated 2006 February; cited 2008 May 1]. Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html.
3. Chung C.T., and Carlson R.W. Goals and objectives in the management of metastatic breast cancer. Oncologist 8 (2003) 514-520
4. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence. SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission. Bethesda, MD: US National Cancer Institute; [updated 2005 April; cited 2008 May 22]. Available at http://seer.cancer.gov/statfacts/html/breast.html.
5. Honig S.F. Treatment of metastatic disease. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). Diseases of the Breast (1996), Lippincott-Raven Publishers, Philadelphia 634-669
6. American Cancer Society. Cancer Facts & Figures 2008 (2008), American Cancer Society, Atlanta, Georgia
7. Beslija S., Bonneterre J., Burstein H., et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18 (2007) 215-225
8. Moulder S., and Hortobagyi G.N. Advances in the treatment of breast cancer. Clin Pharmacol Ther 83 (2008) 26-36
9. Andre F., Slimane K., Bachelot T., et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 22 (2004) 3302-3308
10. Sparano J.A. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1 (2000) 32-42
11. Blackwell K.L. The significance of distant metastases in breast cancer. Breast 17 Suppl 1 (2008) S1-S2
12. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 Suppl 3 (2005) 20-29
13. Chia S.K., Speers C.H., D'yachkova Y., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110 (2007) 973-979
14. Lipton A., Cook R.J., Major P., et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 12 (2007) 1035-1043
15. Ringel I., and Horwitz S.B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83 (1991) 288-291
16. USA Food and Drug Administration (FDA) Center for Drug Evaluation and Research. FDA Oncology Tools Approval Summary for paclitaxel for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Rockville, MD: US Food and Drug Administration; [cited 2008 May 22]. Available at http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=125.
17. Giordano S.H., Duan Z., Kuo Y.F., et al. Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst 98 (2006) 382-388
18. Radaideh S.M., and Sledge G.W. Taxane vs. taxane: is the duel at an end? A commentary on phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat (2007 Nov 8) [Epub ahead of print].
19. Harries M., Ellis P., and Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol 23 (2005) 7768-7771
20. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 (1999) 2341-2354
21. Verrill M.W., Lee J., Cameron D.A., et al. Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase 3 pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Oncol 25 18S part I (2007) LBA1005 [abstract].
22. Nabholtz J.M., Gelmon K., Bontenbal M., et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14 (1996) 1858-1867
23. Winer E.P., Berry D.A., Woolf S., et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol 11 (2004) 2061-2068
24. ten Tije A.J., Verweij J., Loos W.J., et al. Pharmacological effects of formulation vehicles. Implications for cancer chemotherapy. Clin Pharmacokinet 42 (2003) 665-685
25. Gelderblom H., Verweij J., Nooter K., et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37 (2001) 1590-1598
26. van Zuylen L., Verweij J., and Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19 (2001) 125-141
27. TAXOL® (paclitaxel) Injection [prescribing information] (2007), Bristol-Myers Squibb Company, Princeton, NJ
28. TAXOTERE® (docetaxel) Injection Concentrate [prescribing information] (2007), Sanofi aventis U.S. LLC, Bridgewater, NJ
29. Boyle D.A., and Goldspiel B.R. A review of paclitaxel (Taxol) administration, stability, and compatibility issues. Clin J Oncol Nurs 2 (1998) 141-145
30. Waugh W.N., Trissel L.A., and Stella V.J. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 48 (1991) 1520-1524
31. Onetto N., Dougan M., Hellmann S., et al. Safety profile. In: McGuire W.P., and Rowinsky E.K. (Eds). Paclitaxel in Cancer Treatment (1995), Marcel Dekker, New York 21-149
32. Wiedenmann N., Valdecanas D., Hunter N., et al. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res 13 (2007) 1868-1874
33. Ibrahim K.N., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremaphor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8 (2002) 1038-1044
34. Maeda H., Wu J., Sawa T., et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000) 271-284
35. Tiruppathi C., Song W., Bergenfeldt M., et al. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 272 (1997) 25968-25975
36. Ng S.S.W., Sparreboom A., Shaked Y., et al. Influence of formulation vehicle on metronomic taxane chemotherapy: Albumin-bound versus Cremophor EL-based paclitaxel. Clin Cancer Res 12 (2001) 4331-4338
37. Desai N., Trieu V., Yao Z., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compare with Cremophor-based paclitaxel. Clin Cancer Res 12 (2006) 1317-1324
38. Kiessling F., Fink C., Hansen M., et al. Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas. Use of a low-loaded, covalently bound Gd-HAS conjugate as contrast agent with high tumor affinity. Investigative Rad 37 (2002) 193-198
39. Watkins G., Douglas-Jones A., Bryce R., et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72 (2005) 267-272
40. Chin D., Boyle G.M., Williams R.M., et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113 (2005) 789-797
41. Trieu V., Frankel T., Labao E., et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Proc Amer Assoc Cancer Res 46 (2005) 5584 [abstract].
42. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7 (2006) 1041-1052
43. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
44. Henderson I.C., and Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 7 (2007) 919-943
45. Syed S.K., Beeram M., Takimoto J., et al. Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. J Clin Oncol 22 14S (2004) 2028 [abstract].
46. Genta Incorporated. Tesetaxel: clinical program. Berkeley Heights; NJ: Genta Incorporated Website; [cited 2008 June 10]. Available at http://www.genta.com/tesetaxel.html.
47. Kuppens I.E., Bosch T.M., van Maanen M.J., et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol 55 (2005) 72-78
48. Bröker L.E., de Vos F., van Groeningen C.J., et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 12 (2006) 1760-1767
49. ClinicalTrials.gov. Studies of BMS-275183 in lung and solid tumor cancers. Bethesda, MD: US National Institute of Health; [cited 2008 April 19]. Available at http://clinicaltrials.gov/ct2/results?term=BMS-275183.
50. ClinicalTrials.gov. Oral taxane in combination with pemetrexed (Alimta) in patients with recurrent non-small cell lung cancer. Bethesda, MD: US National Institute of Health; [updated 2007 August 27; cited 2008 April 19]. Available at http://clinicaltrials.gov/ct2/show/NCT00103831.
51. National Cancer Institute. Paclitaxel poliglumex. Bethesda, MD: US National Cancer Institute; [cited 2008 April 19]. Available at http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=38325.
52. ClinicalTrials.gov. Open studies of paclitaxel poliglumex in squamous cell, lung, prostate, esophageal and ovarian cancers. Bethesda, MD: US National Institute of Health; [cited 2008 June 2]. Available at http://clinicaltrials.gov/ct2/results?term=paclitaxel+and+poliglumex&recr=Open&type=&cond=&intr=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e=.
53. ClinicalTrials.gov. Paclitaxel poliglumex and capecitabine in treating patients with metastatic breast cancer. Bethesda, MD: US National Institute of Health; [updated 2008 May 23, cited 2008 June 2]. Available at http://clinicaltrials.gov/ct2/show/NCT00265733?term=NCT00265733&rank=1.
54. National Cancer Institute. Phase II study of paclitaxel poliglumex (CT-2103; Xyotax™) and capecitabine in patients with metastatic breast cancer. Bethesda, MD: US National Cancer Institute; [cited 2008 June 2]. Available at http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=456449&version=HealthProfessional&protocolsearchid=4650618.
55. National Cancer Institute. Paclitaxel vitamin E-based emulsion formulation. Bethesda, MD: US National Cancer Institute; [cited 2008 April 19]. Available at http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=474798.
56. ClinicalTrials.gov. Evaluation of safety and efficacy of TOCOSOL(R) paclitaxel as initial treatment for metastatic breast cancer. Bethesda, MD: US National Institute of Health; [updated 2007 September 10, cited 2008 June 2]. Available at http://clinicaltrials.gov/ct2/show/NCT00096668?term=NCT00096668&rank=1.